Positive Drug Results, Market Activity Updates, Sustainability Report, Acquisitions, and Plant Closure - Research Reports on Repros, Jazz, Ingersoll-Rand, Nokia and Duke Energy

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 2, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Repros Therapeutics Inc. (NASDAQ: RPRX), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Ingersoll-Rand Plc (NYSE: IR), Nokia Corporation (NYSE: NOK) and Duke Energy Corporation (NYSE: DUK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6149-100free.

--
Repros Therapeutics Inc. Research Reports
On August 27, 2014, Repros Therapeutics Inc. (Repros) reported top line results for the first of two identical pivotal studies that compared Androxal® to a leading topical gel (Androgel® 1.62) approved by FDA and placebo. The study, ZA-305, found that the Androxal showed superiority in several assessments, particularly the two co-primary endpoints: percent change from baseline in average sperm concentration and percent of subjects considered to be responders. The study showed 33.3% reduction from baseline sperm concentration for Topical T subjects versus 5.9% increase for Androxal subjects ITT. Furthermore, the responder rate for Topical T was 33.3%, compared with 65.9% rate for Androxal® ITT. Additionally, multiple secondary endpoints showed statistically significant differences between the Androxal® and T gel groups. Cheering the positive results, the Company's stock rallied 18.51% on August 28, 2014. Repros stated that it expects to submit an NDA around the end of 2014. If approved, Androxal® would represent the first drug therapy to specifically target secondary hypogonadism. The full research reports on Repros are available to download free of charge at:

http://www.analystsreview.com/Sep-02-2014/RPRX/report.pdf

--
Jazz Pharmaceuticals Plc Research Reports
On August 28, 2014, the stock of Jazz Pharmaceuticals Plc (Jazz) fell 0.25% to end the trading session at $162.71. During the session, the stock opened at $162.11, and oscillated in the range of $161.11 - $163.94. Jazz's stock has a 52-week high of $176.60 and a 52-week low of $80.40. Over the last one month, the stock has witnessed an increase of 16.14%, outperforming the Dow Jones Industrial Average which rose 0.99% during that period. The full research reports on Jazz are available to download free of charge at:

http://www.analystsreview.com/Sep-02-2014/JAZZ/report.pdf

--
Ingersoll-Rand Plc Research Reports
On August 21, 2014, Ingersoll-Rand Plc (Ingersoll Rand) released its 2013 Sustainability Supplement detailing the Company's efforts towards sustainable growth. According to the Company, its 2013 sustainability supplement provides data that shows how the enterprise strategy of pursuing excellence in growth, operations and culture is leading to measurable successes. "Our performance goals focus on embedding sustainability into our DNA; addressing climate change; being truthful and transparent in communications; advocating for the right things; and building a winning culture," said W. Scott Tew, Executive Director, Center for Energy Efficiency & Sustainability (CEES) at Ingersoll Rand. Ingersoll Rand said it has reduced normalized energy consumption and normalized greenhouse gas (GHG) emissions by 36% over the last five years; created savings of over $200,000 in environmental initiatives in 2013; achieved a cost savings of $2 million at its Arecibo, Puerto Rico facility, amongst other achievements. The full research reports on Ingersoll-Rand are available to download free of charge at:

http://www.analystsreview.com/Sep-02-2014/IR/report.pdf

--
Nokia Corporation Research Reports
On August 25, 2014, Nokia Corporation's (Nokia) network arm Nokia Networks announced that it has completed the acquisition of Schaumburg, Illinois-based SAC Wireless to further enhance its existing network implementation service capabilities. According to Nokia Networks, this acquisition is expected to increase its market share in this space and also bring clear revenue synergies. SAC Wireless will operate as a wholly-owned subsidiary of Nokia. "With a national footprint and a proven track record of working with major telecom operators, SAC Wireless' capabilities complement our own in-house expertise. We believe this will enable us to build an even stronger foundation for our U.S. services business and address a market opportunity to bring increased end-to-end efficiency to our customers," said Ricky Corker, Executive Vice President of North America for Nokia Networks. The full research reports on Nokia are available to download free of charge at:

http://www.analystsreview.com/Sep-02-2014/NOK/report.pdf

--
Duke Energy Corporation Research Reports
On August 28, 2014, Duke Energy Corporation (Duke Energy) announced that it will retire the remaining coal-fired units, 5 and 6, at its W.C. Beckjord Station in New Richmond, Ohio, effective September 1, 2014. The move is part of the Company's previously announced plan to retire Beckjord Station's coal-fired units 1 through 6 - totaling 862 megawatts (MW) of generating capacity - by January 1, 2015, due to stringent regulations on power plant emissions imposed by the U.S. Environmental Protection Agency. Beckjord unit 1 was retired in 2012; units 2 and 3 were retired in 2013; and unit 4 retired earlier this year. The Company informed that other than the employees necessary for the transition to decommissioning, current Beckjord employees will be relocated to nearby Duke Energy Ohio plants. The full research reports on Duke Energy are available to download free of charge at:

http://www.analystsreview.com/Sep-02-2014/DUK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…